CRISPR Therapeutics director Ali Behbahani disposes of common shares worth $780,649.24
CRISPR Therapeutics director Ali Behbahani exercised stock options for 30,000 common shares at USD 14 on Sept. 17, 2026. Behbahani sold 13,679 common shares at USD 57.09 on the same day. * Directly held common shares totaled 16,637 following the transactions. Disclaimer: This news brief was created by Public Technologi